Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

FDA drug alerts in pulmonology, including drug approvals/warnings, vaccine approvals, medical device recalls/updates, and drug label updates.

Pneumococcal vaccination may reduce the risk for pneumonia-related morbidity and mortality among patients with immune-mediated inflammatory diseases.

mycoplasma pneumoniae (a common bacterial infection that usually affects younger children), respiratory syncytial virus (RSV) and SARS-CoV-2 (the virus causing Covid-19). The authorities stressed ...

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...

The following is a summary of “Respiratory viral infections from 2015 to 2022 in the HIVE cohort of American households: Incidence, illness characteristics, and seasonality,” published in the August ...

“Make a plan now for you and your family to get both updated flu and COVID vaccines this fall, ahead of the respiratory virus season.”Here’s what to know about the vaccines available to ...

“Make a plan now for you and your family to get both updated flu and COVID vaccines this fall, ahead of the respiratory virus season.” We don’t know how effective these vaccines will be in ...

Although the causative pathogens differ depending on treatment setting and patient factors, Streptococcus pneumoniae is the primary pathogen in all treatment settings. As a class, the respiratory ...